# A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients

> **NCT03099876** · — · UNKNOWN · sponsor: **Il-Yang Pharm. Co., Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **PROCEDURE:** treatment period

## Key facts

- **NCT ID:** NCT03099876
- **Lead sponsor:** Il-Yang Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2017-12-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099876, "A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03099876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*